[go: up one dir, main page]

CL2022001167A1 - Treatment of liver disorders - Google Patents

Treatment of liver disorders

Info

Publication number
CL2022001167A1
CL2022001167A1 CL2022001167A CL2022001167A CL2022001167A1 CL 2022001167 A1 CL2022001167 A1 CL 2022001167A1 CL 2022001167 A CL2022001167 A CL 2022001167A CL 2022001167 A CL2022001167 A CL 2022001167A CL 2022001167 A1 CL2022001167 A1 CL 2022001167A1
Authority
CL
Chile
Prior art keywords
treatment
liver disorders
disorders
manifestations
symptoms
Prior art date
Application number
CL2022001167A
Other languages
Spanish (es)
Inventor
Weidong Zhong
Martijn Fenaux
Yujin Wang
Kevin Klucher
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of CL2022001167A1 publication Critical patent/CL2022001167A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En este documento se proporcionan métodos y composiciones para tratar trastornos hepáticos, incluyendo, sin limitación, esteatohepatitis no alcohólica, y síntomas y manifestaciones de los mismos, en un paciente.Provided herein are methods and compositions for treating liver disorders, including, without limitation, non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient.

CL2022001167A 2019-11-08 2022-05-04 Treatment of liver disorders CL2022001167A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962933277P 2019-11-08 2019-11-08
US202063004403P 2020-04-02 2020-04-02

Publications (1)

Publication Number Publication Date
CL2022001167A1 true CL2022001167A1 (en) 2023-02-10

Family

ID=75849579

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001167A CL2022001167A1 (en) 2019-11-08 2022-05-04 Treatment of liver disorders

Country Status (11)

Country Link
EP (1) EP4054567A4 (en)
JP (1) JP2023501386A (en)
KR (1) KR20220098168A (en)
CN (1) CN114667142A (en)
AU (1) AU2020380968A1 (en)
BR (1) BR112022008639A2 (en)
CA (1) CA3160445A1 (en)
CL (1) CL2022001167A1 (en)
IL (1) IL292459A (en)
MX (1) MX2022005407A (en)
WO (1) WO2021092474A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259279A1 (en) 2020-12-14 2023-10-18 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US20140187633A1 (en) * 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
CA3019496A1 (en) * 2016-03-28 2017-10-05 Intercept Pharmaceuticals, Inc. Medicine obtained by combining fxr agonist and arb
US20200131129A1 (en) * 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2019023245A1 (en) * 2017-07-25 2019-01-31 Cedars-Sinai Medical Center Methods for treating liver diseases
JP2022508402A (en) * 2018-08-30 2022-01-19 ターンズ・ファーマシューティカルズ・インコーポレイテッド Treatment of liver disorders

Also Published As

Publication number Publication date
WO2021092474A1 (en) 2021-05-14
EP4054567A1 (en) 2022-09-14
KR20220098168A (en) 2022-07-11
AU2020380968A1 (en) 2022-05-12
JP2023501386A (en) 2023-01-18
IL292459A (en) 2022-06-01
MX2022005407A (en) 2022-05-24
CN114667142A (en) 2022-06-24
EP4054567A4 (en) 2024-01-10
CA3160445A1 (en) 2021-05-14
BR112022008639A2 (en) 2022-07-19

Similar Documents

Publication Publication Date Title
ZA202204929B (en) Rimegepant for cgrp related disorders
CO2020004301A2 (en) 1-Benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors
MX2021002305A (en) Treating liver disorders.
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
CR20190354A (en) HIV INHIBITING COMPOUNDS
ECSP17073878A (en) DERIVED FROM INDOL MONO OR DISUSTITUTED AS INHIBITORS OF THE VIRAL REPLICATION OF DENGUE
MX385332B (en) ROR-GAMMA MODULATORS.
EA202092490A1 (en) METHYL-MODIFYING ENZYMES MODULATORS, COMPOSITIONS AND THEIR APPLICATION
EA201692487A1 (en) PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
EA201892075A1 (en) COMBINATION OF LSD1 INHIBITORS FOR USE FOR THE TREATMENT OF SOLID TUMORS
MX2017001656A (en) Bruton's tyrosine kinase inhibitor combinations and uses thereof.
CL2019002240A1 (en) Therapeutic dendrimers.
MX2021015854A (en) COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS.
EA201692268A1 (en) PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
MX2022005563A (en) TYK2 PSEUDOKINASE LIGANDS.
MX2019007892A (en) Metalloenzyme inhibitor compounds.
BR112022009710A2 (en) COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR
PH12021550671A1 (en) Prodrugs of cgrp antagonists
CR20220071A (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING SPINAL MUSCULAR ATROPHY
CL2022001167A1 (en) Treatment of liver disorders
EA202191115A1 (en) NEW PYRIDAZINES
MX2022006812A (en) Methods for treating copd by administering an il-33 antagonist.
MX2022005250A (en) THERAPEUTIC COMBINATIONS OF ACALABRUTINIB AND CAPIVASERTIB TO TREAT MALIGNANT NEOPLASMS OF B LYMPHOCYTES.
MX2021006915A (en) Cxcr7 inhibitors for the treatment of cancer.